Akebia Therapeutics Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Rule

Akebia Therapeutics, Inc. (AKBA) announced it received a deficiency notice from the Nasdaq Stock Market on October 21, 2026. The notice was issued because the company's common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, a violation of Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the company's stock listing.

Key Details

• Compliance Period: Akebia has an initial 180-calendar day period, until April 19, 2027, to regain compliance with the minimum bid price requirement.
• Compliance Requirement: To regain compliance, the closing bid price of the company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days.
• Company Action: The company intends to monitor its closing bid price and is evaluating all available options to regain compliance, which could include a reverse stock split.